News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Hapoalim Securities Expects Eli Lilly and Company To Acquire Amylin Pharmaceuticals, Inc. Post Approval Of AMLN’s Bydureon
June 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Benzinga.com -- Analyst Jon LeCroy of Hapoalim Securities reiterates his "buy" rating on Amylin Pharmaceuticals (NASDAQ: AMLN). The target price for AMLN is set to $22.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Eli Lilly and Company
MORE ON THIS TOPIC
Deals
An Insmed takeout by Sanofi would be ‘clear strategic fit’ in respiratory space
November 20, 2026
·
2 min read
·
Heather McKenzie
Cancer
Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
November 20, 2026
·
3 min read
·
Gabrielle Masson
Earnings
Novartis projects slowed growth, pins hopes on billions in pipeline potential
November 19, 2026
·
3 min read
·
Annalee Armstrong
Licensing
AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal
November 19, 2026
·
1 min read
·
Annalee Armstrong